GlassScriptPhysician profile
Luis A Delgado Mateu
NPI 1568586287
$38,896.54
in general payments reported to CMS, 2019-2025
38 companies · $8,544 in 2025
The $8,544 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,646 · 2020: $4,934 · 2021: $4,594 · 2022: $6,174 · 2023: $4,054 · 2024: $2,950 · 2025: $8,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,023 · Consulting Fee: $5,400 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,023.25 |
| Consulting Fee | $5,400.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13,707.83 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Abbvie INC. | $6,374.83 | 2019-2025 | Venclexta, Epkinly, Lupron Depot |
| Merck Sharp & Dohme LLC | $6,245.57 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $1,804.62 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Celgene Corporation | $1,637.71 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $1,543.64 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| Pbg Puerto Rico LLC | $1,345.99 | 2019-2025 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $1,167.82 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $1,030.23 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Novartis Pharmaceuticals Corporation | $832.11 | 2019-2025 | |
| Amgen INC. | $559.33 | 2019-2025 | Xgeva, Lumakras, Kyprolis |
| Genzyme Corporation | $429.41 | 2019-2025 | |
| Bayer Puerto Rico INC. | $352.09 | 2023-2025 | Nubeqa, Stivarga, Vitrakvi |
| Glaxosmithkline, LLC. | $335.95 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Exelixis INC. | $293.72 | 2019-2025 | Cabometyx |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $139.88 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.08 | 2022 | |
| Taiho Oncology, INC. | $118.19 | 2019-2022 | |
| Puma Biotechnology, INC. | $117.05 | 2019-2025 | |
| Astellas Pharma US INC | $106.36 | 2023-2025 | Xospata, Vyloy |
| Regeneron Healthcare Solutions, INC. | $91.41 | 2023-2025 | Libtayo |
| Caris Mpi, INC. | $65.94 | 2025 | Mi Cancer Seek |
| Bayer Healthcare Pharmaceuticals INC. | $62.78 | 2020-2022 | |
| Morphosys, US INC. | $49.06 | 2023 | Monjuvi |
| Mirati Therapeutics, INC. | $48.04 | 2024 | Krazati |
| Incyte Corporation | $47.56 | 2023-2025 | Pemazyre, Monjuvi, Jakafi |
| Verity Pharmaceuticals INC. | $38.25 | 2022-2023 | Akynzeo |
| Array Biopharma INC | $30.73 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Organon LLC | $25.00 | 2025 | |
| Sobi, INC | $22.95 | 2024 | |
| Emd Serono, INC. | $22.95 | 2023 | Bavencio |
| Clovis Oncology, INC. | $21.17 | 2019 | |
| Cti Biopharma Corp. | $20.20 | 2023 | Vonjo |
| Tempus Ai, INC | $19.94 | 2024 | Xt Cdx |
| Pharmacyclics LLC, An Abbvie Company | $17.69 | 2023 | Imbruvica |
| Pfizer Pharmaceuticals LLC | $16.95 | 2019 | |
| Eisai INC. | $16.45 | 2023 | |
| Seagen INC. | $14.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Delgado Mateu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.